Trials / NCT04224207
Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells
Completed Phase 3 Cell therapy
- Sponsor
- Ankara Universitesi Teknokent
- Treatment
- Wharton's jelly derived mesenchymal stem cell
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Inherited Retinal Dystrophy
- Ages
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Started
- 2019-04-01
- Main results expected
- 2019-10-30
- Results posted
- Not yet
- Record last updated
- 2020-01-13
What the study is testing
The aim of this study is to determine if umbilical cord Wharton's jelly derived mesenchymal stem cells implanted in sub-tenon space have beneficial effects on visual functions in retinitis pigmentosa patients by reactivating the degenerated photoreceptors in dormant phase.
Where it runs
Turkey (Türkiye) (2)
- Ankara University Biotechnology Institute, Ankara, Türkiye
- Umut Arslan, Ankara, Türkiye